Exclusive analysis of biotech, pharma, and the life sciences
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
G ood morning, everyone, and how are you today? We are doing just fine, thank you. Given that this is already the middle of the week and we have survived this far, there is no reason not to continue, yes? Just consider the alternatives. In fact, this modest accomplishment calls for celebration. So please join us in quaffing a ritual cup of needed stimulation. Our choice today is cinnamon hazelnut. Or grab a bottle of water, if you prefer. Meanwhile, here are a few items of interest to help you along. Once again, we hope you have a successful day and, of course, keep in touch. We enjoy hearing your tips and tidbits. …
Moderna chair Noubar Afeyan launched an unflinching defense of the board’s executive hiring process after it was forced to fire its new chief financial officer last week following just one day in the job, The Financial Times tells us. Afeyan dismissed suggestions the board could have done anything differently, insisting it had asked all the right questions but was not told about an internal investigation into financial reporting at Jorge Gomez’s former employer due to legal constraints. Afeyan said the executive search company contracted by Moderna was also blameless because it was unaware of the probe by dental equipment maker Dentsply Sirona, which was disclosed last week.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
Ed covers the pharmaceutical industry.
This name will appear with your comment
There was an error saving your display name. Please check and try again.
By Tara Bannow and Bob Herman
Reporting from the frontiers of health and medicine